shuijuan Shen

Ms. shuijuan Shen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Seminars in Dialysis
Verified
Journal Article
Closed access
JWJiaying Wu
Jiaying Wu
SLShuangxiang Lin
Shuangxiang Lin
JGJichao Guan
Jichao Guan
XWXiujuan Wu
Xiujuan Wu
MDMiaojia Ding
Miaojia Ding
SSshuijuan Shen
shuijuan Shen

25 June 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ZRZhouhao Ren
Zhouhao Ren
JWJiaying Wu
Jiaying Wu
SWShaorui Wu
Shaorui Wu
MZMengwei Zhang
Mengwei Zhang
SSshuijuan Shen
shuijuan Shen
Background: There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with the prognosis in multiple types of cancers. Like in cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationships between the ALI and all-cause and cardiovascular disease (CVD) mortality in PD patients. Methods: Patients who started PD at Shaoxing People’s Hospital between 1 January 2013 and 31 December 2020 (n = 277) were recruited and followed up until 1 July 2023. They were divided into high-ALI group and low-ALI group according to the median of ALI. Kaplan–Meier curves and multivariate Cox regression analyses were used to assess the associations between the ALI and all-cause and CVD mortality. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to determine the predictive power of the ALI for all- cause and CVD mortality. Results: During the median follow-up of 40.50 months (interquartile range, 26.42–59.77 months), a total of 55 patients died, 31 of whom died due to CVD. Kaplan–Meier curves revealed that patients in the low-ALI group had significantly lower cumulative and cardiovascular cumulative survival rates than did those in the high-ALI group (all P < 0.001). After we corrected for confounders, the risk of all-cause and CVD mortality was significantly greater in the low-ALI group than in the high-ALI group [hazard ratio (HR) 1.944, 95% confidence interval (CI) 1.068–3.540, P = 0.030, and HR 2.672, 95% CI 1.188–6.009, P = 0.017, respectively]. The predictive value of ALI (AUC = 0.708, 95% CI 0.630–0.786, P < 0.001) for all-cause mortality was superior to albumin (AUC = 0.644, 95% CI 0.556–0.726, P < 0.001), body mass index (AUC = 0.581, 95% CI 0.496–0.659, P = 0.069) and neutrophil-to-lymphocyte ratio (AUC = 0.675, 95% CI 0.596–0.754, P < 0.001). Conclusion: A lower ALI is an independent risk factor for all-cause and cardiovascular mortality in PD patients. The ALI may be an effective indicator for predicting outcomes in PD patients.

1 February 2023 in Nephrologie & Therapeutique
Verified
Journal Article
Closed access
PDF file
JWJiaying Wu
Jiaying Wu
JGJichao Guan
Jichao Guan
SLShuangxiang Lin
Shuangxiang Lin
XWXiujuan Wu
Xiujuan Wu
MDMiaojia Ding
Miaojia Ding
SSshuijuan Shen
shuijuan Shen
Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia. Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded. Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin. Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.

23 July 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
ZSZheng Shaoxiong
Zheng Shaoxiong
XZXiumei Zhou
Xiumei Zhou
YQYuan Qin
Yuan Qin
YXYu Xiaomei
Yu Xiaomei
CLChen Lingli
Chen Lingli
BHBiao Huang
Biao Huang
Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are <10%. The specificity of our Kim‐1‐TRFIA is acceptable. The recovery is between 95.14% and 102.84%. The concentration of Kim‐1 in the serum of patients with AKI is 126.50 ± 67.99 pg/ml, which is significantly higher than that in the serum of healthy controls (49.72 ± 16.40 pg/ml, p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.

26 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
ZRZhouhao Ren
Zhouhao Ren
JWJiaying Wu
Jiaying Wu
SSshuijuan Shen
shuijuan Shen
Background There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with prognosis in multiple types of cancers. Similar to cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationship between ALI and all-cause and cardiovascular mortality in PD patients. Methods 277 patients who started PD at Shaoxing People's Hospital between 1 January 2013 and 31 December 2020 were recruited and followed up until 1 July 2023. The dose-response relationship between ALI and mortality was described by restricted cubic splines. Receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated to determine the predictive power of ALI for all- cause mortality and CVD mortality. Kaplan-Meier curves and multivariate cox regression analyses were used to assess the association between ALI and all-cause mortality and cardiovascular mortality. Result During the median follow-up of 40.50 months (interquartile range, 26.42~59.77 months), a total of 55 patients died and 31 of them died due to cardiovascular disease. Kaplan-Meier curves showed that patients in the low ALI group had significantly lower cumulative survival rate and cardiovascular cumulative survival rate than those in the high ALI group (all P < 0.001). After correcting for confounders, the risk of all-cause mortality and cardiovascular death was significantly higher in the low ALI group than in the high ALI group [hazard ratio (HR) 1.944, 95% confidence interval (Cl) 1.068~3.540, P = 0.030, and HR 2.672, 95% Cl 1.188~6.009, P = 0.017, respectively]. Conclusion A lower ALI is an independent risk factor for all-cause mortality and cardiovascular mortality in PD patients. ALI may be an effective indicator for predicting outcomes in PD patients.

30 July 2024 in Seminars in Dialysis
Verified
Journal Article
Closed access
XWXiujuan Wu
Xiujuan Wu
SWShaorui Wu
Shaorui Wu
JSJuanping Shan
Juanping Shan
SSshuijuan Shen
shuijuan Shen
XDXuan Deng
Xuan Deng